Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect.
MicroMarvel Neurogene Challenges Big Pharma Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases.
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing improved safety and efficacy.
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024.
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024.
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
